Guideline adherence in bone-targeted treatment of cancer patients with bone metastases in Germany
Open Access
- 14 August 2019
- journal article
- research article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 28 (5) , 2175-2184
Abstract
Purpose To assess adherence to the current European Society for Medical Oncology (ESMO) clinical practice guideline on bone health in cancer patients and the German guidelines for lung, breast, and prostate cancer among German oncologists in hospitals and office-based physicians and to identify predictors of guideline compliance to assess the needs for dedicated training. Methods This was a retrospective sample analysis representing hospitals and office-based physicians in Germany in 2016. Records from lung, breast, and prostate cancer patients who had received a diagnosis of bone metastasis between April 1, 2015, and March 31, 2016, were included. Oncologists at participating centers answered a self-assessment survey on aspects related to their professional life, including guideline adherence and years of clinical experience in medical oncology. Guideline adherence rates were assessed from patient records. Treatment variables and survey data were used to identify predictors of guideline compliance in a Classification and Regression Tree (CART) analysis. Results Disregarding recommendations for supplementation of calcium and vitamin D, guideline adherence among physicians treating lung, breast, or prostate cancer patients was 62%, 92%, and 83%, respectively. Compliance was 15%, 42%, and 40% if recommendations for dietary supplements were taken into account. Identified predictors of guideline compliance included treatment setting, medical specialty, years of professional experience, and frequency of quality circle attendance. Conclusions Compliance with the ESMO and the German guidelines in cancer patients varies between medical specialties. In particular, patients with lung cancer and bone metastases often do not receive the recommended osteoprotective treatment and required supplementation. Discrepancies between guideline recommendations and common practice should be addressed with dedicated training.Keywords
Funding Information
- Amgen GmbH Germany (AIO-SUP-0116)
This publication has 20 references indexed in Scilit:
- Cost of skeletal complications from bone metastases in six European countriesJournal of Medical Economics, 2016
- Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy—a representative sample survey in GermanySupportive Care in Cancer, 2015
- Cancer Treatment-Induced Bone Loss in women with breast cancerBoneKEy Reports, 2015
- Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancerCurrent Opinion in Oncology, 2014
- Bone health in cancer patients: ESMO Clinical Practice GuidelinesAnnals of Oncology, 2014
- Survival in breast cancer patients with bone metastases and skeletal-related events: a population-based cohort study in Denmark (1999–2007)Breast Cancer Research and Treatment, 2011
- Skeletal Related Events, Bone Metastasis and Survival of Prostate Cancer: A Population Based Cohort Study in Denmark (1999 to 2007)Journal of Urology, 2010
- Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow—a long-term follow-upAnnals of Oncology, 2008
- Statistical Modeling: The Two Cultures (with comments and a rejoinder by the author)Statistical Science, 2001
- Reduction in New Metastases in Breast Cancer with Adjuvant Clodronate TreatmentNew England Journal of Medicine, 1998